Homocysteine (Hcy) is a sulfur-containing amino acid derived from methionine metabolism that has emerged as a significant contributor to neurodegenerative disease pathogenesis. Elevated levels of homocysteine (hyperhomocysteinemia) have been consistently associated with increased risk of Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative conditions. This page examines the molecular mechanisms through which homocysteine exerts neurotoxic effects, its vascular contributions to neurodegeneration, and the therapeutic implications of homocysteine-lowering strategies.
The relationship between homocysteine and neurodegeneration was first identified through epidemiological studies showing that individuals with elevated plasma homocysteine had approximately double the risk of developing dementia[1]. Subsequent research has revealed multiple overlapping mechanisms through which homocysteine contributes to neuronal dysfunction, including oxidative stress, endoplasmic reticulum stress, mitochondrial dysfunction, and vascular damage.
Homocysteine is generated from methionine through demethylation and exists in two primary forms:
The metabolism of homocysteine occurs through two primary pathways:
Remethylation pathway: Homocysteine is remethylated to methionine using 5-methyltetrahydrofolate (folate) as the methyl donor, with vitamin B12 as a cofactor. This reaction is catalyzed by methionine synthase (MS).
Transsulfuration pathway: Homocysteine is condensed with serine to form cystathionine via cystathionine β-synthase (CBS), requiring vitamin B6 as a cofactor. Cystathionine is subsequently converted to cysteine.
Several genetic variants affect homocysteine metabolism:
Homocysteine induces oxidative stress through multiple mechanisms[2]:
Free Radical Generation:
Antioxidant System Impairment:
Lipid Peroxidation:
In PD models, homocysteine directly impairs mitochondrial function[3]:
Homocysteine triggers ER stress through:
Recent research has identified homocysteine as an inducer of ferroptosis[4]:
Homocysteine acts as an NMDA receptor agonist:
Homocysteine disrupts cellular autophagy mechanisms[5]:
Homocysteine affects epigenetic regulation[6]:
Homocysteine directly impairs synaptic function[7]:
Homocysteine activates inflammatory pathways[8]:
Homocysteine damages the vascular endothelium[9]:
Hcy compromises BBB integrity:
Vascular contributions to neurodegeneration:
Elevated homocysteine is a recognized risk factor for AD[1:1]:
In AD, homocysteine contributes through multiple pathways:
B vitamin deficiency is common in AD[10][11]:
B vitamin supplementation trials have shown mixed results[12][13]:
PD patients commonly exhibit hyperhomocysteinemia[14]:
Homocysteine contributes to PD pathogenesis through[3:1][15]:
Levodopa treatment significantly affects homocysteine levels[16]:
Homocysteine is a major contributor to cerebral small vessel disease[17]:
Managing Hcy in PD:
Elevated Hcy is observed in ALS patients[18]:
Homocysteine may serve as an ALS biomarker[19]:
Lowering homocysteine through vitamin supplementation:
| Vitamin | Mechanism | Typical Dose |
|---|---|---|
| Folic acid | Methyl donor for remethylation | 0.4-5 mg/day |
| Vitamin B12 | Cofactor for methionine synthase | 0.5-1 mg/day |
| Vitamin B6 | Cofactor for transsulfuration | 10-50 mg/day |
Non-pharmacological approaches:
Emerging therapeutic approaches:
Treatment targets:
Homocysteine represents a modifiable risk factor for neurodegenerative diseases. The multiple mechanisms through which homocysteine exerts neurotoxic effects—including oxidative stress, mitochondrial dysfunction, ER stress, and vascular damage—provide a rationale for homocysteine-lowering strategies. While B vitamin supplementation effectively reduces homocysteine levels, the clinical benefits for neurodegenerative disease prevention and treatment remain uncertain. Further research is needed to identify which patient subgroups may benefit most from homocysteine-lowering interventions and to determine the optimal timing and intensity of treatment.
Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med. 2009. ↩︎ ↩︎
Dumont M, Vigneault C, Lépine F, et al. Homocysteine and oxidative stress in Alzheimer's disease. J Alzheimers Dis. 2021. ↩︎
Chen S, Li Z, He Y, et al. Homocysteine induces mitochondrial dysfunction in Parkinson's disease. Free Radic Biol Med. 2022. ↩︎ ↩︎
Lu H, Liu X, Deng Y, et al. Hyperhomocysteinemia promotes Parkinson's disease via ferroptosis. Aging Cell. 2021. ↩︎
Tjiatt L, Chen J, Wang M, et al. Homocysteine induces autophagy impairment in Alzheimer's disease. Cell Death & Disease. 2021. ↩︎
Xie Y, Liu Y, Wang J, et al. "DNA hypomethylation induced by homocysteine in neurodegeneration". Epigenetics. 2023. ↩︎
Hou L, Wang R, Zhang L, et al. Homocysteine and synaptic dysfunction in Alzheimer's disease. J Neurosci Res. 2022. ↩︎
Yang W, Zhou H, Liu Q, et al. "Homocysteine promotes neuroinflammation via NLRP3 inflammasome activation". Glia. 2024. ↩︎
Sun Y, Chen Y, Liu L, et al. "Homocysteine and cerebrovascular disease in dementia". Stroke. 2023. ↩︎
Clarke R, Smith D, Jobst KA, et al. Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer's disease. Arch Neurol. 1998. ↩︎
Lehmann M, Regland B, Blennow K, et al. Vitamin B12 and folate in Alzheimer's disease and mild cognitive impairment. J Nutr Health Aging. 2021. ↩︎
Smith AD, Smith SM, de Jager CA, et al. "Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial". PLoS ONE. 2010. ↩︎
Wang Y, Li M, Tang J, et al. B vitamin supplementation reduces progression of brain atrophy in Alzheimer's disease. Neurology. 2019. ↩︎
Ozbek Z, Ozkok A, Tatlı L, et al. "Hyperhomocysteinemia in Parkinson disease: cause or consequence?". J Clin Neurosci. 2019. ↩︎
Li J, Xin L, Wang L, et al. Homocysteine-mediated neurotoxicity in Parkinson's disease models. Neuropharmacology. 2022. ↩︎
Liu X, Chen H, Lin Z, et al. B vitamins and cognitive decline in Parkinson's disease. Neurology. 2022. ↩︎
Zhang M, Li Y, Wang J, et al. "Homocysteine and cerebral small vessel disease in neurodegenerative disorders". Stroke. 2023. ↩︎
Kumar A, Singh P, Garg N, et al. "Role of homocysteine in the pathogenesis of ALS". Amyotroph Lateral Scler Frontotemporal Degener. 2019. ↩︎
Pant S, Rao A, Patel V, et al. "Homocysteine as a biomarker for disease progression in ALS". Ann Clin Transl Neurol. 2023. ↩︎